The Phase 2b COPERNICUS study, which followed 214 U.S. patients, highlights a shift toward more manageable treatment protocols. By utilizing prophylactic strategies to mitigate common issues like blood clots and dermatological reactions, researchers observed that only eight percent of patients discontinued the regimen due to adverse events at a median follow-up of 8.3 months.

Specifically, the subcutaneous approach yielded notably lower complication rates than those recorded in the earlier MARIPOSA study. Rash was reported in 25 percent of the COPERNICUS cohort, while administration-related reactions and venous thromboembolism each occurred in three percent of participants. These figures contrast sharply with the MARIPOSA trial, where rates for these events were significantly higher. By integrating once-monthly dosing and pragmatic clinical design, Johnson & Johnson aims to simplify the treatment journey for diverse patient populations across both community and academic medical centers.